AGIOS PHARMACEUTICALS INC. - COMMON STOCK

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

18 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

08 ديسمبر 2024 12:40:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

11 نوفمبر 2024 09:45:31 بحسب NetDania Notify

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

08 نوفمبر 2024 09:55:39 بحسب NetDania Notify

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

07 نوفمبر 2024 14:59:27 بحسب NetDania Notify

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

05 نوفمبر 2024 09:05:00 بحسب Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

31 أكتوبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

23 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

17 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

26 سبتمبر 2024 09:45:10 بحسب NetDania Notify

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

11 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

05 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

06 أغسطس 2024 17:50:17 بحسب Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

01 أغسطس 2024 06:31:00 بحسب Nasdaq GlobeNewswire

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

01 أغسطس 2024 06:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

23 يوليو 2024 10:53:30 بحسب NetDania Notify

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

18 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

15 يونيو 2024 08:45:00 بحسب Nasdaq GlobeNewswire

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET

06 يونيو 2024 09:00:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

05 يونيو 2024 09:46:01 بحسب NetDania Notify